Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye

Phase 3CompletedNCT00037661

Merck Sharp & Dohme LLC222 enrolled

Overview

Comparative efficacy trial of INS365 Ophthalmic Solution and placebo in patients with dry eye.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

222

Conditions

Keratoconjunctivitis Sicca

Interventions

INS365 Ophthalmic SolutionDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * have Non-Sjogren's associated dry eye disease with symptoms lasting greater than 6 months * had intermittent or regular artificial tear use within past 3 months Exclusion Criteria: * had LASIK surgery * had punctal occlusion or cauterization within last 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.